Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak

Dawid Maciorowski, Christian Ogaugwu, Subba Rao Durvasula, Ravi Durvasula, Adinarayana Kunamneni

Research output: Contribution to journalReview articlepeer-review


An outbreak of the coronavirus disease 2019 (COVID-19) caused by an infection of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China, in December 2019. This new virus belongs to the group of enveloped RNA beta-coronaviruses. Symptoms may differ in various infected persons, but major presentations include dry cough, nasal congestion, shortness of breath, fever, and general malaise. The disease appears to be more severe in patients above the age of 60 years and those with underlying conditions such as diabetes, cancer, cardiovascular diseases, chronic respiratory disease, and hypertension. There is still no approved vaccine against COVID-19, but more than a hundred are at different stages of development. It is known that the development of new drugs takes a relatively long time, so several known and already-approved drugs are being repurposed for the treatment of this disease. In this review, we explore the therapeutic and vaccine options that are available for COVID-19 6 months after its outbreak. Most noteworthy among the therapeutic options are dexamethasone, remdesivir, Avigan (favipiravir) and convalescent plasma.

Original languageEnglish (US)
Pages (from-to)311-329
Number of pages19
JournalSLAS Discovery
Issue number3
StatePublished - Mar 2021


  • COVID-19
  • SARS-CoV-2
  • drug repurposing
  • therapeutics
  • vaccines

ASJC Scopus subject areas

  • Biotechnology
  • Analytical Chemistry
  • Biochemistry
  • Molecular Medicine


Dive into the research topics of 'Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak'. Together they form a unique fingerprint.

Cite this